ISPOR 16th Annual International Meeting
May 21-25, 2011 • Hilton Baltimore • Baltimore, MD, USA
Health Care Reform and Comparative Effectiveness Research – Where Have We Been and Where Are We Going?

PROGRAM

Early Registration Deadline: April 5, 2011
Over 1300 abstracts submitted!

KEY INFORMATION

MEETING PROGRAM COMMITTEE
Program Committee Chair
Mark S. Roberts, MD, MPP, Professor and Chair, Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health & Professor of Medicine, Industrial Engineering and Clinical and Translational Science, University of Pittsburgh, Pittsburgh, PA, USA
Research Review Committee Co-Chairs
Murtuza Bharmal, PhD, MS, Director, Quintiles, Rockville, MD, USA
Teresa B. Gibson, PhD, MS, MA, Director, Health Outcomes, Thomson Reuters (Health-care), Ann Arbor, MI, USA
Yi Yang, MD, PhD, Assistant Professor of Pharmacy Administration and Research Assistant Professor, Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS, USA

RESEARCH POSTER PRESENTATIONS
POSTER PRESENTATIONS SESSION I: MONDAY, MAY 23
Set-up: 7:30AM - 8:00AM
Poster Display Hours: 8:00AM - 8:30PM
Poster Author Discussion Hour: 6:30PM - 7:30PM
Dismantle: 8:30PM - 9:00PM

POSTER PRESENTATIONS SESSION II: TUESDAY, MAY 24
Set-up: 7:30AM - 8:00AM
Poster Display Hours: 8:00AM - 7:45PM
Poster Author Discussion Hour: 6:15PM - 7:15PM
Dismantle: 7:45PM - 8:15PM

POSTER PRESENTATIONS SESSION III: WEDNESDAY, MAY 25
Set-up: 7:30AM - 8:00AM
Poster Display Hours: 8:00AM - 3:00PM
Poster Author Discussion Hour: 11:45AM - 12:45PM
Dismantle: 3:00PM - 3:30PM

VENUE INFORMATION/HOTEL RESERVATIONS
HILTON BALTIMORE
401 West Pratt St., Baltimore, MD 21201
The Hilton Baltimore is located 15 minutes from the Baltimore/Washington Thurgood Marshall International Airport (BWI) and within 10 minutes walking distance to Baltimore’s Inner Harbor district and leading tourist attractions.

MEETING PROMOTIONAL/EMPLOYMENT OPPORTUNITIES
EXHIBIT
SOLD OUT! 300
ADVERTISE
ADVERTISE in the Program & Schedule of Events! ADVERTISING DEADLINE: APRIL 4, 2011
SPONSOR
Give your company increased visibility and prominence.
EMPLOYMENT – ePRAP
Post your job opening or submit your CV.

FOR MORE INFO: WWW.ISPOR.ORG

ISPOR Rates: The discounted room rate for ISPOR Meeting attendees is $199.00, plus applicable taxes. Discounted rates are available until April 29, 2011 (subject to availability).
Reservations: Must be made using the Baltimore Hilton online reservation system available at www.ispor.org or by calling 1-800-HILTONS (Event name: ISPOR 16th Annual International Meeting). Cancellations or changes to reservations without penalty must be made by April 20, 2011.
Financial Impact / Cost of Illness
Josephine Mauskopf, PhD, RTI Health Solutions; C. Daniel Mullins, PhD, University of Maryland
Know methods to determine the cost-of-illness of a health condition using a “top-down” or “bottom-up” approach. Learn how to estimate the impact of new health care technologies.

Modeling: Design and Structure of a Model
Mark S. Roberts, MD, MPP, University of Pittsburgh
Review Markov models and other techniques, referencing the ISPOR Principles of Good Practice for Decision Analytic Modeling in Health Care Evaluations. Evaluate practical steps in developing and using these models.

NEW! Meta-Analysis & Network Meta-Analysis in Comparative Effectiveness Research
Joseph C. Cappelleri, MD, MPH, Pfizer Inc.
Analyze the following key areas: comparative effectiveness research; impetus for meta-analytic and systematic reviews; basic steps to quantitative systematic reviews; statistical methods of combining data; reporting results; appraisal and use of meta-analytic reports; network meta-analysis for indirect treatment comparisons.

Patient Registrars
Leanne Larson, MHA, Outcome
Review applications in identifying “real world” clinical, safety, and patient-perspective issues. Pros and cons of registry data, strategy, design, operations and measures of program success are discussed.

Bayesian Analysis – Advanced
Keith R. Abrams, PhD, University of Leicester
Review the use of Markov Chain Monte Carlo methods in conducting policy-relevant outcomes research. Engage in hands-on exercises that address methodological issues and the role of Bayesian methods in policy-making.

Applications in Using Large Databases
Diana Brixner, PhD, RPh, University of Utah; Michael Eddy, PhD, PharmD, Xcenda; John Parkinson PhD, GPRD
Numerous databases are discussed in-depth including directions on accessing information and how researchers utilize this information.

Patient-Reported Outcomes – Item Response Theory
Bryce Reeve, PhD, University of North Carolina at Chapel Hill
Review the basics of IRT models and their applications to improve health outcomes measurement.

Conjoint Analysis – Theory & Methods
A. Brett Hauber, PhD, RTI Health Solutions; John F. P. Bridges, PhD, Johns Hopkins Bloomberg School of Public Health
Discuss the conceptual basis for quantifying decision-maker preferences for medical interventions and practical design and analytical issues that must be addressed to obtain valid empirical preference estimates.

Utility Measures
Andrew Lloyd, DPhil; Sarah Acaster, MSc, Oxford
Explore methods used to capture utilities such as standard gamble, time trade off and rating scales, and discuss instruments to measure quality of life such as the EQ-5D, Health Utilities Index and SF-36.

Case Studies in Pharmaceutical/Biotech Pricing II – Advanced
Jack M. Mycka, MME LLC; Renato Dellamano, PhD, MME Europe & ValuVector
Case studies analyze new product pricing, focusing on the need to thoroughly evaluate the business environment and the need to integrate pricing, reimbursement and pharmacoeconomics strategies with clinical development and marketing strategies.

Statistical Considerations in Health Economic Evaluations
Henry Glick, PhD; Jaala A. Doshl, PhD, University of Pennsylvania
Discuss effect of distributional assumptions, analyze univariate and multivariable analysis data, censored data, sample size and power calculations, sampling uncertainty, point estimates for variables, net monetary benefit, and confidence intervals for cost-effectiveness ratios.

Applications of Statistical Considerations in Health Economic Evaluations
Henry Glick, PhD; Jaala A. Doshl, PhD, University of Pennsylvania
Specific exercises illustrate effect of distributional assumptions, univariate & multivariable analysis of costs, the effect of sample size & power calculations on economic evaluations, point and estimates for cost-effectiveness ratios.

Risk-Sharing/Performance-Based Arrangements
Adrian Towse, MA, MPhil, Office of Health Economics; Lou Garrison, PhD; Josh Carlson, PhD, University of Washington
Theory and practice, including incentives and barriers, of these arrangements are analyzed using examples of performance-based schemes from Europe, the United States, and Australia.

Outcomes Research for Medical Devices and Diagnostics
Seema Sonnad, PhD, University of Pennsylvania; Stacey Ackerman, MSE, PhD, Covance Market Access Services
Outcomes research for medical devices and diagnostics is differentiated from other health care interventions. Evidence hierarchy for medical devices and diagnostic procedures is discussed.

Propensity Scores and Observational Studies of Treatment Effect
John Seeger, PharmD, DrPh, Harvard Medical School/B Brigham and Women’s Hospital
Bias and methods for causal inference in observational studies, as well as how propensity scores can reduce bias are discussed. Risk adjustment models, confounding, pros and cons of standard adjustment and propensity scoring methodology are reviewed.

Advanced Patient-Reported Outcomes Assessment – Psychometric Methods
Bruce Crawford, MPH, MA; Stacie HUDGINS, MA (AbD), Mapi Values
Psychometric application and the analysis of various techniques (structural equation modeling, factor analysis, and item response theory) in testing patient-reported outcomes instruments, measures and construct / criterion validity are discussed.

Establishing the Content Validity of Patient-Reported Outcome (PRO) Instruments
Donald L. Patrick, PhD, MSPH, University of Washington; Mona L. Martin, RN, NPA, Health Research Associates, Inc; Chad Gwaltney, PhD, Brown University
Requirements for establishing content validity of PRO instruments, definitions of evidence requirements, issues necessitating clarity, and logistical needs for gathering acceptable evidence are covered. Practical exercises are used to establish evidence of content validity for PRO instruments.

Advanced Decision Modeling for Health Economic Evaluations
Andrew Briggs, PhD, University of Glasgow; Mark Sculpher, PhD, MSc, University of York
Key aspects in the development of decision modeling, how models can be made probabilistic to capture parameter uncertainty, and how to analyze and present results are discussed. Interpretation of results and decision making are presented.
Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

Moderator: Peter J. Neumann, ScD

Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA

PRESIDENTIAL ADDRESS
Mark S. Roberts, MD, MPP,

The importance of prospective observational research in the health economics and outcomes research portfolio for demonstrating post-approval safety and comparative value will be highlighted. Speakers will address strategic and operational planning, including the importance of accommodating the expectations of key internal and external stakeholders. (Sponsored by the National Pharmaceutical Council)

ISPOR STUDENT RESEARCH COMPETITION

The use of advanced technological solutions within the area of global pricing and market access, new ways to use technological solutions to integrate processes, market access data and advanced analytics, and the benefits of such integration will be identified. (Sponsored by Aditya Health)

SUNDAY, MAY 22, 2011

8:00AM - 5:00PM PRE-MEETING SHORT COURSES

5:15PM - 6:15PM EDUCATIONAL SYMPOSIUM

CHALLENGES AND OPPORTUNITIES OF PROSPECTIVE OBSERVATIONAL RESEARCH

The importance of prospective observational research in the health economics and outcomes research portfolio for demonstrating post-approval safety and comparative value will be highlighted. Speakers will address strategic and operational planning, including the importance of accommodating the expectations of key internal and external stakeholders. (Sponsored by the National Pharmaceutical Council)

6:00PM - 7:30PM ISPOR STUDENT RESEARCH COMPETITION

7:30PM - 8:30PM ISPOR STUDENT & FACULTY ICEBREAKER RECEPTION

MONDAY, MAY 23, 2011

7:00AM - 8:00AM EDUCATIONAL SYMPOSIUM

NAVIGATING THE NEW COMPARATIVE EFFECTIVENESS LANDSCAPE

Manufacturers of biopharmaceuticals and medical devices are faced with a rapidly changing external environment with the emergence of comparative effectiveness research (CER). What CER will mean exactly in practice, and when new methods and evidence standards will come into effect, is still uncertain. How can manufacturers navigate the new CER world? By treating it as a new hurdle or proactively developing their own policies? (Sponsored by IMS)

5:15PM - 6:15PM EDUCATIONAL SYMPOSIUM

RCTS Vs. OBSERVATIONAL STUDIES: THE NEXT GREAT DEBATE IN CER

There are two disparate camps, one believes only a randomized clinical trial (RCT) can truly answer research questions; the other that observational studies data is necessary for research questions applicable to real world settings. Others recognize that both have a role to play, and this symposium will debate which approach is best used. (Sponsored by the National Pharmaceutical Council)

6:30PM - 7:30PM EDUCATIONAL SYMPOSIUM

TECHNOLOGY TRENDS IN GLOBAL PRICING AND MARKET ACCESS

Mini-SENTINEL, the Affordable Care Act and recent initiatives to extend and enhance commercial datasets will be reviewed and the implications for HEOR and our ability to impact the direction of health decision making will be discussed. (Sponsored by IMS)

8:00AM - 5:00PM PRE-MEETING SHORT COURSES

1:45PM - 2:45PM LUNCH, EXHIBITS & POSTER PRESENTATIONS – SESSION I

12:00PM - 1:45PM ENDEAVOURS: IMPLICATIONS FOR OUTCOMES RESEARCH

The direction and specific accomplishments of recent innovations in health data collection and data management that could reshape health economics and outcomes research (HEOR), such as Mini-SENTINEL, the Affordable Care Act and recent initiatives to extend and enhance commercial datasets will be reviewed and the implications for HEOR and our ability to impact the direction of health decision making will be discussed. (Sponsored by IMS)

1:45PM - 2:45PM RESEARCH PODIUM PRESENTATIONS – SESSION I

CANCER OUTCOMES RESEARCH

CN1: MONOTHERAPY OF ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL PROSTATECTOMY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER: A COMPARATIVE EFFECTIVENESS ANALYSIS USING RETROSPECTIVE CANADIAN REGISTRY DATA BEFORE AND AFTER DRUG APPROVAL

Khor S, Bremner K, Krahm M, Hodgson D, Hoch J, ‘Cancer Care Ontario, Toronto, ON, Canada, ‘University Health Network, Toronto, ON, Canada, ‘Toronto Health Economics and Technology Assessment (THEA) Collaborative, Toronto, ON, Canada, ‘Princess Margaret Hospital, Toronto, ON, Canada

IP1: PAYING FOR VALUE - WHICH TO GO FOR: THE NEW GERMAN LAW OR NEITHER?

Moderator: J. Jaime Caro, MDCM, FRCP(C), FACP, FC, United BioSource Corporation, Lexington, MA, USA
Panelists: Peter L. Kolominsky-Rabas, MD, PhD, MBA, Centre for Health Technology Assessment (HTA) and Public Health (DHP), University of Erlangen-Nuremberg, Erlangen, Germany; Alistair J. McGuire, PhD, LSE Health and Social Care, London, UK

IP3: ASSESSMENTS OF RELATIVE EFFECTIVENESS: THE NEXT GREAT DEBATE IN CER

Moderator: Benedikte Lensberg, MSc, 13 Innocus, Uxbridge, Middlesex, UK

IP4: WHAT CAN WE LEARN FROM SUCCESSES AND FAILURES IN PERSONALIZED MEDICINE?

IMPLICATIONS FOR EVOLVING HEALTH ECONOMICS AND OUTCOMES RESEARCH PRACTICES

Moderator: Eric C. Faulkner, MPH, RTI Health Solutions, Research Triangle Park, NC, USA
Panelists: Bruce Quinn, PhD, MD, Foley Hoag, Boston, MA, USA; Kostas Trakas, PhD, MSc, Johnson & Johnson Pharmaceutical Services LLC, Toronto, ON, Canada; Lou Garrison, PhD, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

IP5: DEBATING THE VALUE AND FUTURE DIRECTIONS OF PATIENT REGISTRIES IN COMPARATIVE EFFECTIVENESS RESEARCH

Moderator: Nancy Dreyer, PhD, MPH, Outcome, Cambridge, MA, USA
Panelists: Charles E. Barr, MD, MPH, Genentech, Inc., South San Francisco, CA, USA; John Spertus, MD, MPH, University of Missouri-Kansas City, Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO, USA; Robert McDonough, MD, JD, MPP, Aetna, Hartford, CT, USA

IP2: PAYING FOR VALUE - WHICH TO GO FOR: THE NEW GERMAN LAW OR NEITHER?

Moderator: J. Jaime Caro, MDCM, FRCP(C), FACP, FC, United BioSource Corporation, Lexington, MA, USA
Panelists: Peter L. Kolominsky-Rabas, MD, PhD, MBA, Centre for Health Technology Assessment (HTA) and Public Health (DHP), University of Erlangen-Nuremberg, Erlangen, Germany; Alistair J. McGuire, PhD, LSE Health and Social Care, London, UK

IP3: ASSESSMENTS OF RELATIVE EFFECTIVENESS: THE NEXT GREAT DEBATE IN CER

Moderator: Benedikte Lensberg, MSc, 13 Innocus, Uxbridge, Middlesex, UK

IP4: WHAT CAN WE LEARN FROM SUCCESSES AND FAILURES IN PERSONALIZED MEDICINE?

IMPLICATIONS FOR EVOLVING HEALTH ECONOMICS AND OUTCOMES RESEARCH PRACTICES

Moderator: Eric C. Faulkner, MPH, RTI Health Solutions, Research Triangle Park, NC, USA
Panelists: Bruce Quinn, PhD, MD, Foley Hoag, Boston, MA, USA; Kostas Trakas, PhD, MSc, Johnson & Johnson Pharmaceutical Services LLC, Toronto, ON, Canada; Lou Garrison, PhD, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA

IP5: DEBATING THE VALUE AND FUTURE DIRECTIONS OF PATIENT REGISTRIES IN COMPARATIVE EFFECTIVENESS RESEARCH

Moderator: Nancy Dreyer, PhD, MPH, Outcome, Cambridge, MA, USA
Panelists: Charles E. Barr, MD, MPH, Genentech, Inc., South San Francisco, CA, USA; John Spertus, MD, MPH, University of Missouri-Kansas City, Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, MO, USA; Robert McDonough, MD, JD, MPP, Aetna, Hartford, CT, USA

12:00PM - 1:45PM LUNCH, EXHIBITS & POSTER PRESENTATIONS – SESSION I

12:30PM - 1:30PM EDUCATIONAL SYMPOSIUM

NEW PATIENT-LEVEL DATA FROM SENTINEL, ACA AND RECENT COMMERCIAL ENDOWEMENTS: IMPLICATIONS FOR OUTCOMES RESEARCH

The direction and specific accomplishments of recent innovations in health data collection and data management that could reshape health economics and outcomes research (HEOR), such as Mini-SENTINEL, the Affordable Care Act and recent initiatives to extend and enhance commercial datasets will be reviewed and the implications for HEOR and our ability to impact the direction of health decision making will be discussed. (Sponsored by IMS)

1:45PM - 2:45PM RESEARCH PODIUM PRESENTATIONS – SESSION I
PHARMACEUTICALS CORPORATION Medical, East Hanover, NJ, USA; Jie Zhang, PhD, Novartis Pharmaceuticals Corporation Medical, East Hanover, NJ, USA

W3: PATIENT-CENTERED BENEFIT-RISK ANALYSIS: THE CASE FOR ANALYTIC HIERARCHY PROCESS
Discussion Leaders: Maarten J. IJzerman, PhD, Department of Health Technology & Services Research, University Twente, Enschede, The Netherlands; John F.P. Bridges, PhD, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Sonal Singh, MD, MPH, Division of General Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.

W4: CHOOSING PRO STATISTICAL ENDPOINTS TO MAXIMIZE SUCCESSFUL OUTCOMES
Discussion Leaders: Dennis D. Gagnon, MA, MABE, Thomson Reuters, Santa Barbara, CA, USA; Margaret Rothman, PhD, Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA

W5: USING CMS MEDICARE CLAIMS PUBLIC USE FILES (PUGS) FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)
Discussion Leaders: Samuel C. “Chris” Haffer, PhD, Office of Research, Development, & Information, Centers for Medicare and Medicaid Services (CMS), Baltimore, MD, USA; Craig G. Coeelen, PhD, IMPAQ International, LLC, Columbia, MD, USA; Elizabeth C. Hair, PhD, NRC at the University of Chicago, Bethesda, MD, USA; Jane Hyatt Thorpe, JD, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, Washington, DC, USA

W6: POWERFUL DATA, MEANINGFUL ANSWERS: INTRODUCTION TO THE HEALTHCARE COST AND UTILIZATION PROJECT
Discussion Leaders: Claudia Steiner, MD, MPH, Center for Delivery, Organization and Markets (CDOM), Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA; Lauren M. Wier, MPH, Thomson Reuters, Cambridge, MA, USA

16:30PM - 17:30PM WORKSHOPS – SESSION II
W7: NEW METHODS TO ADJUST FOR SELECTIVE CROSSOVER IN SURVIVAL ANALYSES: IN ASSESSMENTS OF COST-EFFECTIVENESS OF CANCER THERAPIES
Discussion Leaders: Thomas E. Delea, MSIA, Policy Analysis Inc. (PAI), Brookline, MA, USA; Mei-Sheng Duh, MPH, ScD, Analysis Group, Inc., Boston, MA, USA; Lee-Jen Wei, PhD, Harvard University, Boston, MA, USA; James Robins, MD, Harvard School of Public Health, Boston, MA, USA

W8: BRICS & MORTAR: BUILDING EMERGING MARKETS INTO GLOBAL HEOR PROGRAMS
Discussion Leaders: David Thompson, PhD, 13 Innovus, Medford, MA, USA; Gabriela Tannus, MSc, Astra.Bio, Sao Paulo, Brazil; Jiamel Xu, PhD, Pfizer, New York, NY, USA

W9: USING COMPARATIVE EFFECTIVENESS RESEARCH (CER) TO SUPPORT A VALUE-BASED HEALTH CARE SYSTEM, EXAMPLES FROM THE UNITED STATES AND EUROPE
Discussion Leaders: Rachael Fluorence, PhD, United BioSource Corporation, Chyse Chay, MD, USA; Feng Pan, PhD, Center for Health Economics and Science Policy, United BioSource Corporation, Bethesda, MD, USA; Coriina Sorend, MPH, MHSIA, London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK

W10: DEVELOPING BETTER EVIDENCE OF PRODUCT SAFETY
Discussion Leaders: Joshua S. Benner, PharmD, ScD, Engelberg Center for Health Care Reform, The Brookings Institution, Washington, DC, USA; Judy Racoosin, MD, MPH, Office of Medical Policy, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; Patrick Ryan, MEng, Johnon & Johnson Pharmaceutical Research and Development, and Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Bethesda, MD, USA; Jeffrey S. Brown, PhD, Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, USA

W11: PATIENT PREFERENCES AND POLICIES: THE ROLE OF HEALTH-PREFERENCES DATA IN REGULATORY DECISION MAKING
Discussion Leaders: F. Reed Johnson, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; Axel Mühbacher, PhD, Duke Clinical Research Institute/ Fuqua School of Business, Duke University, Durham, NC, USA; Derek S. Brown, PhD, RTI International, Research Triangle Park, NC, USA

W12: INVERSE PROBABILITY-WEIGHTED LEAST SQUARES REGRESSION FOR ESTIMATING POPULATION MEAN COSTS OF ALTERNATIVE INTERVENTIONS USING OBSERVATIONAL DATA
Discussion Leaders: Anthony O’Hagan, PhD, Department of Probability and Statistics, University of Sheffield, Sheffield, UK; Michelle L. Gleen, PhD, Outcomes Insights, Inc., Westlake Village, CA, USA; Mark D. Danese, PhD, Outcomes Insights, Inc., Westlake Village, CA, USA; Robert I. Griffiths, ScD, Outcomes Insights, Inc., Westlake Village, CA, USA

5:30PM - 6:30PM ISPOR FORUMS – SESSION I
WHEN SEEING IS BELIEVING – COMPARATIVE EFFECTIVENESS: ISPOR GOOD PRACTICES TASK FORCE ON PROSPECTIVE OBSERVATIONAL CLINICAL STUDIES
Well-designed observational research has an important role in generating data about comparative effectiveness in real-world clinical practice. Key issues to consider when designing an observational study will be discussed. Presented by the ISPOR Prospective Observational Clinical Studies Task Force

PHARMACOECONOMIC GUIDELINES IN ASIA: FOCUS ON THE CHINA GUIDELINES FOR PHARMACOECONOMIC EVALUATIONS
The forum will introduce the most recent development of the China PE guidelines and will discuss the course of future actions, followed by comments from clinicians and industry, speaking from Asia perspective. Presented by the ISPOR Asia Consortium

CAREER OPTIONS IN THE WAKE OF HEALTH CARE REFORM AND RECESSION
What impact will the implementation of the largest change to the health care system in the United States have on a graduate’s career development? Organized by the ISPOR Student Council

3:00PM - 4:00PM WORKSHOPS – SESSION I
W1: CONDUCTING & INTERPRETING INDIRECT TREATMENT COMPARISON AND NETWORK META-ANALYSIS: LEARNING THE BASICS
Discussion Leaders: Jeroen P. Jansen, PhD, MSc, Mapi Values, Boston, MA, USA; Neil Hawkins, PhD, Oxford Outcomes Ltd., Oxford, UK; Joseph C. Cappelleri, PhD, MPH, Pfizer Inc., New London, CT, USA; Rachael Fluorence, PhD, United BioSource Corporation, Chyse Chay, MD, USA

W2: CHALLENGES AND SOLUTIONS IN CONDUCTING RETROSPECTIVE HEALTH ECONOMICS AND OUTCOMES RESEARCH STUDIES FOR ORPHAN DRUGS AND DISEASES
Discussion Leaders: Peter Sun, MD, PhD, Kailo Research Group, Fishers, IN, USA; Zhimei Liu, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Amy Guo, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

W3: PROJECT LIBRA: A NEW ANALYTICAL TOOL FOR COMPARATIVE EFFECTIVENESS ANALYSES OF MULTIPAY CLAMS DATABASES
Discussion Leaders: Mark T. Pepitone A’, Hatzmann M’, Navathe A’, Goodrick K’, ’Thomson Reuters, Washington, DC, USA; ’Thomson Reuters, Santa Barbara, CA, USA; ’Assistant Secretary for Planning and Evaluation, Washington, DC, USA
DU1: COMPARATIVE SAFETY OF STIMULANT AND Atomoxetine ASSOCIATED WITH THE RISK DRUG USE AND PATIENT SAFETY
Simons WR

DU2: PREVALENCE AND PREDICTORS OF POTENTIALLY SIGNIFICANT DRUG-DRUG INTERAC-
ITIONS IN THE ELDERLY

DU3: IMPACT OF THE FDA’S ANTIPSYCHOTIC BLACK BOX WARNING ON PSYCHOTROPIC DRUG PRESCRIBING IN ELDERLY PATIENTS WITH DEMENTIA IN OUTPATIENT AND OFFICE-BASED SETTINGS
Desai VC, Heaton PC, Kelton C, University of Cincinnati, Cincinnati, OH, USA

DU4: THE LONG TERM UTILIZATION OF STIMULANTS IN CHILDREN AND ADOLESCENTS: A MEDICAID STUDY
Sudharshan L, Chen H, University of Houston, Houston, TX, USA

INFECTION OUTCOMES RESEARCH

DU1: ASSESSMENT OF COMORBITIES AND IMPACT OF INFECTIA: DEVELOPMENT OF THE SYMPTOM INTENSITY AND IMPACT OF INFECTIA QUESTIONNAIRE (FLII-110)

DU2: ASSOCIATION BETWEEN DRUG TOLERABILITY AND ECONOMIC IMPACT FOR PROPHE-
LAXIS OF INVASIVE FUNGAL INFECTION AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT

DU3: COSTS ASSOCIATED WITH HCV AND RELATED COMPLICATIONS IN THE UNITED STATES FROM A MANAGED CARE PAYER’S PERSPECTIVE

DU4: CARDIOVASCULAR DISEASE SCREENING IN HIV-INFECTED PATIENTS: A COST-EFFECT-
IVENESS ANALYSIS
Nolte JEH, Neumann T, Neumann A, Manne J, Mostardt S, Abbara S, Brady TJ, Hoffmann U, Gazelle GS, Wesam J, Goehler A, ‘Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, ‘University Hospital Essen, Essen, Germany, ‘University Duisburg-Essen, Essen, Germany, ‘Harvard School of Public Health, Boston, MA, USA, ‘Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

IMPACT OF MEDICATION COMPLIANCE
MC1: COMPARISON OF REFILL GAP ANALYSIS METHODOLOGIES IN A POPULATION OF PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING ADALIMUMAB OR ETANECETEP
Carber C, Bolge S, Ingham M, Schmeichel-Mueller C, Centocor Ortho Biotech Services, LLC, Horsham, PA, USA

MC2: ASSESSING PREDICTORS OF MEDICATION ADHERENCE IN UNCONDITIONAL QUANTILE REGRESSION FRAMEWORK
Borah B, Mayo Clinic, Rochester, MN, USA

MC3: IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDogeneity BIASES
An J, Nichol MB, University of Southern California, Los Angeles, CA, USA

MC4: LONG TERM PRESENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA
Lokhandwala T, Yang Y, Thumula V, Bentley JP, Strum M, Banahan BF, Nul KD, University of Mississippi, University, MS, USA

5:45AM - 10:45AM RESEARCH PODIUM PRESENTATIONS – SESSION III

HEALTH CARE DECISION-MAKER’S CASE STUDIES
CASE1: THE USE AND PERCEIVED BENEFITS OF ELECTRONIC PRESCRIBING BY BLUE CROSS BLUE SHIELD OF LOUISIANA PHYSICIANS
Soorthonsima O, Campbell C, Shi L, ‘Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA, ‘Tulane University, New Orleans, LA, USA

CASE2: IMPLEMENTING A VALUE-BASED FORMULARY PILLOW IN A U.S. COMMERCIAL SELF-
INSURED EMPLOYER GROUP

CASE3: DETERMINING THE COST EFFECTIVENESS OF A HOSPITAL HEALTH SYSTEM’S USE OF REFERENCE LABORATORIES
Yoder K, Zema C, ‘Excella Health, Greensburg, PA, USA, ‘St. Vincent College, McKenna School of Business, Economics and Government, Latrobe, PA, USA

CASE4: INTEGRATING OUTCOMES INTO DECISION-MAKING BASED ON MAKING HIGH COST DRUGS – A FUNDER CASE STUDY OF THE BIOLOGICAL AGENTS FOR TREATING RHEUMATOID ARTHRITIS
Kopera S, Neil C, Discovery Health, Johannesburg, South Africa

RESEARCH ON METHODS: ECONOMIC EVALUATIONS
EE1: SYSTEMATIC REVIEW OF GUIDELINES FOR HEALTH ECONOMIC EVALUATIONS
Melnyk P, Wagner M, Doudin N, Rindress D, BioMedCom Consultants Inc, Dorval, QC, Canada

EE2: VALIDATION OF THE UPDATED CHARLSON COMORBIDITY INDEX (CCI) TO PREDICT HEALTHCARE UTILIZATION FOR DIABETIC PATIENTS USING ADMINISTRATIVE DATA
Cheng L, Rascali KL, Trice S, Lawson K, Banner JC, ‘The University of Texas at Austin, Austin, TX, USA, ‘Department of Defense, Fort Sam Houston, TX, USA

EE3: PERFORMANCE OF DIFFERENT COMORBIDITY MEASURES IN PREDICTING HEALTH CARE EXPENDITURE IN PATIENTS WITH DEMENTIA
Johnson ML, Mehta S, Chitinis AS, Bhowmik D, Dwivedi N, Kalmbre P, University of Houston, Houston, TX, USA

EE4: BOOTSTRAPPING USED TO PROVIDE ROBUST MEAN AND VARIANCE ESTIMATES FOR COMPARING PATIENTS TREATED WITH LIRAGLUTIDE TO A LARGE COMPARISON COHORT

EVALUATING CONCEPTS IN OUTCOMES RESEARCH
EE1: DEVELOPMENT OF A GUIDANCE FOR INCLUDING PATIENT-REPORTED OUTCOMES (PROS)
IN POST-APPROVAL CLINICAL TRIALS OF ONCOLOGY DRUGS FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)
Basch EM, Abernethy A, Mullins CD, Tugela FD, Turrisi RS. Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Duke University Medical Center, Durham, NC, USA; University of Maryland School of Pharmacy, Baltimore, MD, USA; Center for Medical Technology Policy, Baltimore, MD, USA
EV2: PAYERS AND PROS: BEYOND QOL
Miller KL, Stevens CA, PAREXEL Consulting, Waltham, MA, USA
EV3: A COMPARATIVE EFFECTIVENESS INDEX TO INFORM CLINICAL DECISIONS
Horowitz-Mehl M, Doyle J, Arkin S, Hagan M. Quintiles Global Consulting, Hawthorne, NY, USA; Genesis BioPharma, Hoboken, NJ, USA; New York, NY, USA
EV4: MORE BANG FOR YOUR BUCK: TAKE A RISK WHEN ANALYZING INTERVIEW DATA
Roberts G. Double Helix Consulting Group, London, UK
ANALYSIS OF MEDICARE POLICY AND RESOURCE USE
MD1: USING COST-EFFECTIVENESS INFORMATION TO ALLOCATE MEDICARE RESOURCES – HOW MUCH MORE HEALTH FOR THE MONEY?
Chambers JD, Cohen JT, Neuman PJ, Lord J, Buxton M, Tufts Medical Center, Boston, MA, USA; HERG, Brunel University, Uxbridge, Middlesex, UK
MD2: PRESCRIPTION DRUG COST AND USE IN THE MEDICARE POPULATION – USES OF A NEW LIMITED DATA SET
Peters CA, Varghese A, Hsu VD, O’Donnell J, Schneider K, Centers for Medicare and Medicaid Services, Baltimore, MD, USA; Bucanee, A Vangent Company, Owings Mills, MD, USA; Bucanee, A Vangent Company, West Des Moines, IA, USA
MD3: EVALUATING THE WILLINGNESS-TO-PAY OF MEDICARE BENEFICIARIES FOR PART D PLAN ASSISTANCE
Patel PA, Walberg MP, Na J, Hsiou D, Panchal V, Wuelfel JA, Galla SM, Carr-Lopez SM, Chan EK, University of the Pacific, Stockton, CA, USA
MD4: EVALUATION OF AN INTERVENTION TO REDUCE POLY-PHARMACY IN MEDICARE PART D
Louden KB, Harrell T, Abarca J, WellPoint, Inc., Indianapolis, IN, USA
EXAMINING THE QALY
QA1: COST-EFFECTIVENESS OF DUTASTERIDE AS A CHEMPREVENTION IN PROSTATE CANCER: REDUCE WITHIN-TRIAL ANALYSIS
Earnshaw SR, Chia S, Mckay TS, Black L, Androlle G, Research Triangle Park, NC, USA; GlaxoSmithKline, Research Triangle Park, NC, USA; Washington University School of Medicine in St. Louis, St. Louis, MO, USA
QA2: ESTIMATING A PREFERENCE-BASED SINGLE INDEX FOR CANCER-SPECIFIC INSTRUMENTS FROM THE EQ-5D AND SF-6D
QA3: DOES COST-EFFECTIVENESS ANALYSIS DISCRIMINATE AGAINST PATIENTS WITH SHORTER LIFE EXPECTANCY?
Poulsen T, Culyer A. University of Toronto, Toronto, ON, Canada
QA4: IS THE AIM OF THE HEALTHCARE SYSTEM TO MAXIMIZE QALYS? AN INVESTIGATION OF ‘WHAT ELSE MATTERS’ IN THE NHS
11:00AM - 12:45PM WELCOME & SECOND PLENARY SESSION
INCOMING PRESIDENTIAL ADDRESS
Mark Sculpher, PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK
SECOND PLENARY SESSION: CONDUCTING MEANINGFUL COMPARATIVE EFFECTIVENESS STUDIES IN AN UNCERTAIN POLITICAL ENVIRONMENT
In the American Recovery and Reinvestment Act (ARRA) of 2009, US Congress appropriated $1.1 billion to jump-start the nation’s efforts to accelerate comparative effectiveness research (CER). The US Department of Health and Human Services was responsible for defining priorities and establishing a national comparative effectiveness research agenda. These questions will be addressed during this plenary session.
Moderator: J. Sanford (Sandy) Schwartz, MD, Leon Hess Professor of Medicine, Health Care Management and Economics, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA
Speakers: Carolyn M. Clancy, MD, Director, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, Rockville, MD, USA; Bruce M. Psaty, MD, PhD, Professor, Medicine, Epidemiology and Health Services, University of Washington and Investigator, Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA; Representative from PCORI–TBD
12:45PM - 1:15PM ISPOR AWARDS PRESENTATION
1:15PM - 2:45PM LUNCHE, EXHIBITS, POSTER PRESENTATIONS – SESSION II
1:30PM - 2:30PM EDUCATIONAL SYMPOSIUM
SUPPORTING PERSONALIZED MEDICINE THROUGH A COMPARATIVE EFFECTIVENESS PERSPECTIVE
The interplay between personalized medicine and comparative effectiveness research (CER) may generate novel pharmacoeconomic frameworks with public health implications. This session will focus on current CER efforts on collecting relevant data for understanding differences in effectiveness among different patient populations and how these efforts are critical to the success of personalized medicine. (Sponsored by UBC)
2:45PM - 3:45PM ISSUE PANELS – SESSION II
IP6: WHEN IS THE EVIDENCE ADEQUATE? DIFFERENT PERSPECTIVES FROM KEY HEALTH CARE DECISION-MAKERS
Moderator: Robert W. Dubois, MD, PhD, National Pharmaceutical Council, Washington, DC, USA
Panelists: Bryan R. Luce, MD, MBA, United BioSource Corporation, Bethesda, MD, USA; Steven Pearson, MD, MSc, Institute for Clinical and Economic Review, Boston, MA, USA; Robert S. Epstein, MD, MS, Medco Health, Franklin Lakes, NJ, USA
IP7: HOW DO WE STOP PAYING FOR LOW-VALUE CARE?
Moderator: Sarah Garner, PhD, NICE, London, UK
Panelists: Peter J. Neumann, ScD, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA; Mark Fendrick, MD, Division of General Medicine, Department of Internal Medicine and Department of Health and Management and Policy, University of Michigan Center for Value-Based Insurance Design, Ann Arbor, MI, USA; Adam Elshag, MPH, PhD, School of Population Health and Clinical Practice, Adelaide University/ANaHR, Rockville, MD, USA
IP8: IDENTIFICATION, WEIGHTING AND PRIORITIZATION OF MULTIPLE ENDPOINTS FOR COMPARATIVE EFFECTIVENESS RESEARCH – WHAT HAVE WE LEARNED FROM GERMANY?
Moderator: Michael Drummond, MCom, DHPh, Centre for Health Economics, University of York, Heslington, York, UK
Panelists: Axel Mühlbacher, PhD, Duke Clinical Research Institute/ Fuqua School of Business, Duke University, Durham, NC, USA; John F.P. Bridges, PhD, Department of Health and Policy Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Maarten J. Ijzerman, PhD, Department of Health Technology & Services Research, University Twente, Enschede, The Netherlands
IP9: WILL THE PROPOSED VALUE BASED PRICING WORK IN THE UK?
Moderator: Stephen Beard, MSc, RTI Health Solutions, Sheffield, UK
Panelists: Ron Akehurst, SCiHARR, The University of Sheffield, Sheffield, UK, James Raftery, PhD, Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK; Paul Hodgkins, PhD, MSc, Shire Pharmaceuticals, Wayne, PA, USA
IP10: HOW CAN PATIENT-REPORTED OUTCOMES BECOME A PART OF COMPARATIVE EFFECTIVENESS RESEARCH?
Moderator: C. Daniel Mullins, PhD, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA
Panelists: Ethan Basch, MD, MSc, Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; Amy A. Abemethy, MD, MBA, Duke University, Durham, NC, USA; Albert Wu, Wu, MD, MPH, Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
4:00PM - 5:00PM WORKSHOPS – SESSION III
W13: USE OF SIMULATION TO INFORM THE DESIGN OF PRAGMATIC COMPARATIVE EFFECTIVENESS TRIALS
Discussion Leaders: David Wilson, MA, United BioSource Corporation, Lexington, MA, USA; J. Baird Haggard, MD, FACP, TBIA, The United BioSource Corporation, Lexington, MA, USA; K. Jack Ishak, PhD, MSc, United BioSource Corporation, Dorval, QC, Canada; Myung Kim, PhD, MA, MBA, Health Economics & Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, Ranitan, NJ, USA
W14: MICROECONOMIC TOOLS FOR UNDERSTANDING, MODELING, AND INFLUENCING HEALTHCARE DECISION MAKING
Discussion Leaders: F. Reed Johnson, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; Juan Marcos Gonzalez, PhD, RTI Health Solutions, Research Triangle Park, NC, USA; Deborah A. Marshall, MHA, PhD, McMaster University, Hamilton, Canada
W15: PRACTICAL EXPERIENCES WITH THE USE OF BEST-WORST SCALING IN ECONOMIC EVALUATION
Discussion Leaders: Terry Flynn, PhD, Centre for the Study of Choice (CenSoC), University of Technology, Sydney, NSW, Australia; John F.P. Bridges, PhD, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Christine Poulos, PhD, RTI International, Research Triangle Park, NC, USA
W16: THE EVOLVING ROLE OF THE AGENCY FOR HEALTH CARE RESEARCH AND QUALITY (AHRQ) IN COMPARATIVE EFFECTIVENESS RESEARCH (CER)
Discussion Leaders: Jean Slutska, PS, MSPH, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Nina A. Thomas, MPH, Clinical Affairs & Health Economics, Doctor Evidence, LLC, New York, NY, USA; Steven Blume, MS, Center for Health Economics and Science Policy, United BioSource Corporation, Bethesda, MD, USA
W17: PATIENT-REPORTED OUTCOMES ASSESSMENTS IN CLINICAL TRIALS: NAVIGATING THE EMA AND FDA REGULATORY FRAMEWORK
Discussion Leaders: Ingela Wiklund, PhD, Center for Outcomes Research, United BioSource Corporation, London, UK; Olivier Chassany, PhD, MD, Department of Clinical Research and Development, Assistance Publique-Hopitaux de Paris, Paris, France; Kathleen W. Wynich, PhD, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA
W18: METHODS UTILIZING LONGITUDINAL DATA TO ESTIMATE OF CASUAL EFFECTS IN HEALTH ECONOMICS: ESTIMATION OF TREATMENT EFFECT USING OBSERVATIONAL DATA
Discussion Leaders: William Crown, PhD, 13 Innovus, Waltham, MA, USA; Nilay Shah, PhD, RPh, Mayo Clinic, Rochester, MN, USA; Henry J. Henk, PhD, 13 Innovus, Eden Prairie, MN, USA
5:15PM - 6:15PM ISPOR FORUMS – SESSION II
IP11: COMPARING APPLES TO ORANGES: CONSIDERATIONS FOR USING MIXED METHODS AND MODELS FOR PRO DATA COLLECTION IN CLINICAL TRIALS
Using mixed methods and modes of data collection is on the rise, but what are the risks and benefits? Presented by the ISPOR Patient Outcomes Research Special Interest Group
DESIGNING CONJOIN EXPERIMENTS: A GUIDE TO ALTERNATIVE STRATEGIES
Speakers will present a preliminary guide to the advantages, limitations, and practical implementation of alternative experimental-design methods. Presented by the ISPOR Conjoint Analysis Experimental Design Task Force
DIFFERENCES ON DIFFERENCES: DOES PERSPECTIVE MATTER WHEN CONSIDERING HETEROGENEITY OF TREATMENT EFFECTS

Differences in how individual patients respond to given treatments are of increasing relevance for many stakeholders. The different views of these stakeholders will be debated. Presented by the ISPOR Institutional Council

PHARMACEUTICALS IN BRAZIL: THE CURRENT SITUATION AND FUTURE PERSPECTIVES

This forum will discuss regulatory trends and the current and future state of pharmaceuticals in Brazil. Presented by the ISPOR Brazil Regional Chapter

HEALTH TECHNOLOGY REIMBURSEMENT IN THE CEE REGION: EXPERIENCES FROM COST CONTAINMENT MEASURES FROM POLAND, AND THE SOUTH CENTRAL EUROPEAN REGION

The forum will discuss the changing reimbursement environment in the CEE region and will discuss the short and long term impact of the implementation of cost containment measures. Presented by the ISPOR Poland, Greece and Serbia Regional Chapters

A CHECKLIST FOR POPULATION SELECTION IN ONCOLOGY OUTCOMES RESEARCH USING SECONDARY DATABASES

The importance and challenges in identifying cancer patients in large databases, and a draft checklist of items to be considered when selecting and implementing an algorithm to define a study population will be presented. Presented by the Oncology Outcomes Research Special Interest Group

6:15PM - 7:15PM  POSTER AUTHOR DISCUSSION HOUR – SESSION II

6:15PM - 7:45PM  EXHIBITORS’ WINE & CHEESE RECEPTION & POSTER PRESENTATIONS – SESSION II

8:00PM - 11:30PM  ISPOR SOCIAL EVENT (separate registration required)

Wednesday, May 25, 2011

7:30AM - 8:30AM  EDUCATIONAL SYMPOSIUM

IS HEALTH ECONOMICS AN UN-AMERICAN ACTIVITY?

Cost-effectiveness and the QALY play almost no role in US health decision making, and the very idea of rational allocation of scarce health care resources is politically explosive. Despite excitement about current trends towards comparative effectiveness research, CER is largely impervious to the core methodology of health economics because it excludes costs. Will cost-effectiveness be adopted by US decision-makers? Or should US academics stop teaching methodologies that are never going to be of much practical use, and focus on ‘outcomes research’ instead? (Sponsored by Medivax)

8:00AM - 8:45AM  BREAKFAST, EXHIBITS & POSTER PRESENTATIONS – SESSION III

8:45AM - 9:45AM  ISSUE PANELS – SESSION III

IP11: COVERAGE WITH EVIDENCE DEVELOPMENT IN THE PRIVATE INSURANCE SECTOR: IS IT A PIPE DREAM OR INEVITABLE FOR SOUND POLICY?
Moderator: Penny Mohr, MA, Center for Medical Technology Policy, Baltimore, MD, USA
Panelists: Seema Sonnad, PhD, Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA; Naomi Aronson, PhD, Technology Evaluation Center, Blue Cross Blue Shield Association, Chicago, IL, USA; Russell Teagarden, PharmD, Medco Health Solutions, Inc, Franklin Lakes, NJ, USA

IP12: EXPERIMENTAL VS. OBSERVATIONAL STUDIES: WHICH SHOULD HAVE A HIGHER RANK IN HEALTH CARE DECISIONS?
Moderator: Edward Kim, MD, MBA, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Panelists: C. Daniel Mullins, PhD, Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, MD, USA; Rachael Fleurence, PhD, United BioSource Corporation, Bethesda, MD, USA; Winston Wong, PharmD, CareFirst BlueCross BlueShield, Baltimore, MD, USA

IP13: ARE WE READY FOR A PRIME TIME TO CONDUCT RETROSPECTIVE COMPARATIVE EFFECTIVENESS STUDIES FOR ORPHAN DRUGS AND DISEASES?
Moderator: Lou Garrison, PhD, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA
Panelists: Zhimei Liu, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Amy Guo, PhD, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Peter Sun, MD, PhD, Kaiol Research Group, Fishers, IN, USA

IP14: WHO SHOULD FUND AND HAVE ACCESS TO SECONDARY DATA LINKAGES FOR ONCOLOGY OUTCOMES RESEARCH?
Moderator: Steven B. Clauer, PhD, Outcomes Research Branch, US National Cancer Institute, Bethesda, MD, USA
Panelists: Joseph Lipscomb, PhD, Department of Health Policy & Management, Emory University, Rollins School of Public Health, Atlanta, GA, USA; Cathy J. Bradley, PhD, Department of Healthcare Policy and Research, Virginia Commonwealth University, Richmond, VA, USA; Kathleen Foley, PhD, Thomson Reuters, Cambridge, MA, USA

IP15: DOES PATIENT-REPORTED OUTCOMES ADD VALUE IN HEALTH CARE DECISIONS?
Moderator: Andrea LaFountain, PhD, Mind Field Solutions Corp., Fairfax, VA, USA
Panelists: Michael Manos, MD, Pediatric Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Joseph C. Cappelleri, PhD, MPH, Biostatistics, Pfizer Inc., New London, CT, USA; Mitch Golant, PhD, Research and Training, Cancer Support Community, Washington, DC, USA

10:00AM - 11:30AM  THIRD PLENARY SESSION

MODELING GOOD RESEARCH PRACTICES – EVERYTHING YOU NEED TO KNOW

ISPOR and the Society for Medical Decision Making (SMDM) are jointly developing a series of WORKSHOPS – SESSION VI

W19: IMPROVED INDIRECT TREATMENT COMPARISONS FOR COMPARATIVE EFFECTIVENESS RESEARCH
Discussion Leaders: James Signorovitch, PhD, Analysis Group Inc, Boston, MA, USA; Robert Navarro, PharmD, Navarro Pharma, LLC, Green Cove Springs, FL, USA; Keith Betts, PhD, Analysis Group Inc, Boston, MA, USA; Eric Q. Wu, PhD, Analysis Group Inc., Boston, MA, USA

W20: STOCHASTIC MODELING IN PHARMACEUTICALS – COMMON MISTAKES AND HOW TO AVOID THEM
Discussion Leaders: Francisco J. Zaggmut, DVM, MPVM, Epix Analytics, Boulder, CO, USA; Huybert Groenenendaal, PhD, MSc, MBA, Epix Analytics, Boulder, CO, USA; Marcy Tarrant, MPA, Teva Pharmaceuticals, Kansas City, MO, USA

W21: IMPLEMENTING EPRO IN A GLOBAL CLINICAL TRIAL ENVIRONMENT
Discussion Leaders: Jean Paty, PhD, Inivodova, Inc., Pittsburgh, PA, USA; Jason Jeger, MBA, Inivodova, Inc., Pittsburgh, PA, USA; Agota Szende, PhD, Covance, Leeds, West Yorkshire, UK

W22: ELECTRONIC HEALTH RECORDS AND MEANINGFUL USE: OPPORTUNITIES FOR EVOLUTION IN COMPARATIVE EFFECTIVENESS RESEARCH
Discussion Leaders: Gregory W. Daniel, PhD, RPh, MPH, Government and Academic Research, HealthCore, Inc., Wilmington, DE, USA; Jane Griffin, RPh, Cerner Corporation, Kansas City, MO, USA; Eugene Rich, MD, Center on Health Care Effectiveness, Mathematica Policy Research, Washington, DC, DC, USA; Rolin Wade, RPh, MS, Cerner LifeSciences, Beverly Hills, CA, USA

W23: PRACTICAL APPROACHES FOR SYSTEMATIC ANALYSIS OF OBSERVATIONAL DATA: REAL WORLD CASE STUDIES FROM THE PHARMACEUTICAL INDUSTRY
Discussion Leaders: Jana Kromlhuber, United BioSource Corporation, Harrisburg, PA, USA; Gregory E. Powell, PharmD, MBA, GlaxoSmithKline, Research Triangle Park, NC, USA; David Miller, ScD, SM, Schwarz Bioscience Inc, Raleigh, NC, USA; Jonathan A. Morris, MD, United BioSource Corporation, Blue Bell, PA, USA

3:00PM - 4:00PM  WORKSHOPS – SESSION V

W24: GENERALIZED EVIDENCE SYNTHESIS IN COMPARATIVE EFFECTIVENESS RESEARCH: COULD THE EVIDENCE BASE BE BROADENED IN MIXED TREATMENT COMPARISONS?
Discussion Leaders: Agnes Benedict, MSc, USA, United BioSource Corporation, Budapest, Hungary; Huseynin M. Naqvi, MSc, United BioSource Corporation, London, UK; David Vanness, PhD, Department of Population Health Sciences, University of Wisconsin, Madison, WI, USA

W25: NAVIGATING THE HEOR PUBLICATION PATHWAY: TIPS TO AUTHORS TO FACILITATE MANUSCRIPT ACCEPTANCE IN PRE-REVIEW JOURNALS
Discussion Leaders: Stan Heimerberger, PhD, MBA, MPH, SH Consulting, Franklin Lakes, NJ, USA; Donna Sindress, PhD, BioMedCom Consultants Inc., Donval, DC, Canada

W26: APPLICATION AND USE OF DYNAMIC MODELS IN HEALTH ECONOMIC ANALYSES
Discussion Leaders: Sonya J. Snedecor, PhD, PharmD, Merck, North America LLC, Bethesda, MD, USA; Elamih H. Elbahsa, PhD, Merck & Co., Inc., North Wales, PA, USA; Erik Dobschak, PhD, Merck Research Laboratories, North Wales, PA, USA

W27: PATIENT-CENTRIC OBSERVATIONAL RESEARCH: SUCCESSFULLY DESIGNING AND IMPLEMENTING STUDIES
Discussion Leaders: Elisa Cascade, MBA, MediGuard.org, Rockville, MD, USA; Eric Gemmen, MA, Quintiles, Rockville, MD, USA; Paul Wicks, PhD, PatientLikeMe, Cambridge, MA, USA

W28: ADVANCED MISSING DATA TECHNIQUES IN OBSERVATIONAL RESEARCH: CASE STUDIES IN DATA LINKAGE AND IMPUTATIONS
Discussion Leaders: Christopher M. Blanchette, PhD, MS, MA, GlaxoSmithKline, Research Triangle Park, NC, USA; Alex K. Exuzides, PhD, ICON Clinical Research, San Francisco, CA, USA; William B. Saunders, PhD, MPH, GE Healthcare, Charlotte, NC, USA; Stephen Stemkowski, PhD, MHA, Division of Clinical and Outcomes Research, Lovelace Respiratory Research Institute, Kannapolis, NC, USA
SHORT COURSES

SATURDAY, MAY 21, 2011

All Day Courses 8:00 AM – 5:00 PM
- Introduction to Pharmacoeconomics
- Bayesian Analysis – Overview and Applications
- NEW! Introduction to Design and Analysis of Comparative Effectiveness Studies
- Using Retrospective Databases
- Elements of Pharmaceutical/Biotech Pricing I – Introduction
- Introduction to Modeling
- Cost-Effectiveness Analysis alongside Clinical Trials
- Introduction to Patient-Reported Outcomes
- NEW! Advanced Retrospective Database Analysis: Econometric Methods
- Financial Impact / Cost of Illness
- Modeling: Design and Structure of a Model
- NEW! Conventional and Network Meta-Analysis in Comparative Effectiveness Research
- Patient Registries

SUNDAY, MAY 22, 2011

All Day Course 8:00 AM – 5:00 PM
- Discrete Event Simulation for Economic Analyses
- Bayesian Analysis – Advanced
- Applications in Using Large Databases
- Patient-Reported Outcomes – Item Response Theory
- Conjoint Analysis – Theory & Methods
- Utility Measures
- Case Studies in Pharmaceutical/Biotech Pricing II – Advanced
- Statistical Considerations in Health Economic Evaluations

Afternoon Courses 1:00 PM – 5:00 PM
- Applications of Statistical Considerations in Health Economic Evaluations
- Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products
- Outcomes Research for Medical Devices and Diagnostics
- Propensity Scores and Observational Studies of Treatment Effect
- Advanced Patient-Reported Outcomes Assessment – Psychometric Methods
- Establishing the Content Validity of Patient-Reported Outcome (PRO) Instruments
- Advanced Decision Modeling for Health Economic Evaluations

HALF DAY SHORT COURSE FEES

Registration Before April 5, 2011: REGULAR FEE: US$150 / STUDENT FEE: US$75
Registration After April 5, 2011: REGULAR FEE: US$200 / STUDENT FEE: US$100

ALL DAY SHORT COURSE FEES

Registration Before April 5, 2011: REGULAR FEE: US$300 / STUDENT FEE: US$150
Registration After April 5, 2011: REGULAR FEE: US$400 / STUDENT FEE: US$200

ISPOR Meeting Registration

ISPOR Member | Non-Member*
--- | ---
Standard Registration Before April 5, 2011 | US$650 | US$790
Registration After April 5, 2011 | US$750 | US$890
Clinical Practitioners (Clinical Practice, Hospital) Registration Before April 5, 2011 | US$450 | US$590
Registration After April 5, 2011 | US$550 | US$690
Full-Time Government and Academia Registration Before April 5, 2011 | US$350 | US$490
Registration After April 5, 2011 | US$450 | US$590
Full-Time Students (must provide current enrollment documentation) Registration Before April 5, 2011 | US$150 | US$185
Registration After April 5, 2011 | US$200 | US$235

One Day Registration (per day) **
- May 23 | US$350
- May 24 | US$350
- May 25 | US$350

Continuing Education Accreditation | US$100 | US$100

ISPOR Social Event: Tuesday, May 24
- US$65
- US$40 student

Baltimore Crab Feast on the Inner Harbor

REGISTRATION FEES

<table>
<thead>
<tr>
<th>QTY</th>
<th>FEE</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short Course All Day Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short Course Half Day Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meeting Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social Event</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Continuing Education Accreditation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

TOTAL REGISTRATION FEE: ________________

PAYMENT INFORMATION

Please enclose a check payable in US dollars to: International Society for Pharmacoeconomics and Outcomes Research or ISPOR and send to the ISPOR address given below or charge to: VISA MasterCard American Express Account Number: ___________________ Expiration Date: __________

Name: ____________________________

Mail Details: If not paying by credit card online, send registration form and payment to: International Society for Pharmacoeconomics and Outcomes Research, 3100 Princeton Pike, Building 3, Suite E, Lawrenceville, New Jersey 08648, USA. Tel: 1-609-219-0773 Fax: 1-609-219-0774 E-Mail: info@ispor.org Internet: www.ispor.org

Payment Details: Payment may be made by check, travelers check, bank transfer (there is a USD $40 charge) or credit card. VISA, MasterCard, or American Express will be charged in US dollars. Signature, account number and expiration date must be included. Non-U.S. checks written in U.S. dollars are at no charge. For non-U.S. checks written in foreign currency, bank transfer fees may apply.

Authorized Signature: ________________________

If payment is being made by your company, please make sure your name is indicated on the check stub or correspondence. For bank transfers, please designate the registration name and/or registration number.

Membership Details: If ISPOR cannot verify your current membership, you will be charged the non-member registration rate. When you register as a non-member, you receive an ISPOR membership which includes a one year online subscription to Value in Health - The Journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cancellation Details: Cancellation fee before April 5, 2011 is US$100. No refunds given after April 5, 2011.

FOR MORE INFORMATION: www.ispor.org